Although gemcitabine (GEM) and evofosfamide as monotherapy has a weak effect on MIA Paca-2 and SU 86.86 pancreatic ductal adenocarcinomas respectively, yet the combination therapy shows synergistic effect on both tumor models. The purpose of this study is to understand the synergistic effects of combination therapy using multi-modal imaging methods. In MIA Paca-2 tumors, treatment with GEM induced hypoxia in tumor microenvironment by decreasing the perfusion, which can potentiate evofosfamide. On the other hand, in SU.86.86 tumors, evofosfamide increased blood volume and pO2 in the tumor microenvironment, to potentiate efficacy of anti-proliferatives such as GEM.
This abstract and the presentation materials are available to members only; a login is required.